Skip to content

Cancer Survivorship in Hematologic Malignancies

A Comprehensive Study of Cancer Survivor Syndrome in Adult Egyptian Patients With Hematological Neoplasms

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05780411
Enrollment
80
Registered
2023-03-22
Start date
2023-04-01
Completion date
2025-03-31
Last updated
2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Survivors

Brief summary

General objective: to improve care for haematological cancer survivors. This study will (i) Estimate the incidence of cancer survivor syndrome (CSS) in adult Egyptian patients with haematological neoplasms (HN). (ii) Asses the risk factors of CSS in patients with HN. (iii) Study the effect of CSS on quality of life in patients with HN. (iv) To explore coping strategies of patients with HN having CSS

Detailed description

According to the American Cancer Society the term cancer survivor refersto people who have no signs of cancer after finishing treatment, people receiving extended treatment over a longer period of time to control the cancer or reduce risk of its return, and people with advanced cancer. Most hematologic malignancies (HM) are incurable and typically follow unpredictable remitting-relapsing pathways associated with varying need for treatment, which may be distressing for patients. Distress symptoms and psychological disorders secondary to cancer have also been shown to have significant negative consequences for both the patient and the family. Maladaptive coping and abnormal illness behavior have been associated with psychiatric conditions, with negative effects on adherence to treatment, health behavior, and quality of life (Grassi et al 2017). Moreover, an increased length of stay in the hospital and/or an increased time in rehabilitation have been found to be more common among patients showing psychiatric symptoms, especially depression, than those with normal adjustment to illness (Cordova et al 2017). Unfortunately, cancer-related distress is commonly underrecognized and subsequently undertreated especially for patients with HM in developing countries. Search in literature revealed several screening methods for the psychological consequences of cancer such as Distress Thermometer , Symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire. Also, guidelines for the management of psychological distress have been developed by several scientific cancer associations.

Interventions

OTHERquestionnaire

The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* a. Inclusion criteria: 1. Age will be more than or equal 18 years old regardless with six. 2. Patients have been clinically diagnosed with haematological cancers. 3. Being Native Egyptian patients.

Exclusion criteria

* History of psychiatric disorders. b) Having other concomitant haematological diseases or solid neoplasm or relapse or other chronic disorders

Design outcomes

Primary

MeasureTime frameDescription
The incidence of cancer survivor syndrome (CSS)2 yearsEstimate the incidence of cancer survivor syndrome (CSS) in adult Egyptian patients with hematological neoplasm neoplasms (HN)

Secondary

MeasureTime frameDescription
Asses the risk factors of CSS2 yearsAsses the risk factors of CSS in adult Egyptian patients with hematological neoplasm neoplasms (HN)
Study the effect of CSS on quality of life2 yearsStudy the effect of CSS on quality of life in adult Egyptian patients with hematological neoplasm neoplasms (HN)
Exploring coping strategies2 yearsTo explore coping strategies of adult Egyptian patients with hematological neoplasm neoplasms (HN) in CSS.

Countries

Egypt

Contacts

Backup ContactZain E Ahmed, MD, PhD
Drzain73@yahoo.com01115596820
Primary ContactRoaa M Saleh, MD
roaasalh043@gmail.com00201010617778

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026